Plus Therapeutics Expands CNSide Assay Platform to State of California

Core Insights - CNSide Diagnostics has received lab licenses to provide its proprietary CNSide CSF Tumor Cell Enumeration test in 48 U.S. states, covering over 90% of the U.S. population [1][2] - The CNSide CSF Assay Platform has demonstrated superior clinical utility over standard care, supported by 9 peer-reviewed publications and the FORESEE clinical trial [2] - More than 11,000 CNSide tests have been performed at over 120 U.S. cancer institutions since 2020, achieving high sensitivity of 92% and specificity of 95%, influencing treatment decisions in 90% of cases [3] Company Overview - CNSide Diagnostics, LLC is a wholly-owned subsidiary of Plus Therapeutics, Inc., focused on developing and commercializing proprietary laboratory-developed tests for identifying tumor cells in patients with CNS cancers [4] - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, developing targeted radiotherapeutics for challenging CNS cancers, with a pipeline that includes programs for leptomeningeal metastases and recurrent glioblastoma [5]